🇺🇸 FDA
Pipeline program

Saxenda 6 mg/mL solution for injection in pre-filled pen, Saxenda 6 mg/mL solution for injection in pre-filled pen, Placebo for PF-07976016, Saxenda 6 mg/mL solution for injection in pre-filled pen

C5541010

Phase 2 small_molecule active

Quick answer

Saxenda 6 mg/mL solution for injection in pre-filled pen, Saxenda 6 mg/mL solution for injection in pre-filled pen, Placebo for PF-07976016, Saxenda 6 mg/mL solution for injection in pre-filled pen for Obesity, Overweight is a Phase 2 program (small_molecule) at Pfizer Ireland Pharmaceuticals Unlimited Company with 1 ClinicalTrials.gov record(s).

Program details

Company
Pfizer Ireland Pharmaceuticals Unlimited Company
Indication
Obesity, Overweight
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials